Digital imaging technologies are making the impossible possible -- capture of high resolution 3D images from the sub-angstrom molecular level up to the tissue level. The data associated with these images is growing exponentially at a rate much faster than the radiologists and researchers can keep up. The acceleration and acceptance of artificial intelligence (AI) and machine learning (ML) techniques for image processing provides a perfect opportunity to help solve this problem for humanity.
Health Technology Innovations (HTI) was founded by a team of computer industry veterans with decades of expertise developing and delivering cutting edge technologies to solve complex problems using artificial intelligence, advanced analytics, cloud and internet of things (IoT) solutions. By partnering with leading researchers and visionaries in the healthcare and life sciences industries, HTI is in a unique position to advance the state-of-the-art in medical image processing and data analysis using AI and ML. The end result will be an acceleration of breakthroughs in disease research, drug development and scientific discoveries.
Founder & CEO
VP Market & Business Development
Tuan leads strategy and execution. He founded HTI after spending a successful 26-year career with Intel Corporation that culminated with an inspiring partnership with Oregon Health & Science University. He served as Intel’s Director of Global Pathfinding Operation in the Data Center Innovation Group where he was responsible for $50M in global operations and strategic alliances across the US, Europe and China. From 2010-2012, he also served as the Country Manager and Chief Representative of Intel Vietnam, responsible for driving and delivering $200M in annual revenue. Tuan was a trusted advisor integral in positioning Intel as a leader across multiple countries, as well as establishing Intel’s leadership in USB, PCI Express, InfiniBand, memory, visualization, and power management. He has solid expertise in program management, product marketing, and engineering management. He is a former member of the Oregon Engineering Technology Industry Consortium (ETIC) and holds undergraduate and graduate degrees from Boston University.
Kumar leads machine learning methodology development for cryo-EM image processing with recent experience using TensorFlow. Kumar held numerous technical leadership positions during 36 years at Intel Corporation, including as a software and system developer, systems architect, and senior project manager. He developed real-time operating systems, wireless video streaming, using video compression algorithms and real-time wireless packet video transmission. The wireless streaming protocol, called Miracast, has been adopted in the computer industry and built into an OS. Kumar holds degrees in electrical engineering from the Indian Institute of Technology and computer science from the University of Texas at Arlington.
Shiva leads product development strategy and execution. An expert systems architect and integration specialist, with more than 25 years of experience in the computer industry, including Intel Corporation. His experience includes hardware and software development, engineering management and new technologies enabler (InfiniBand, PCI Express). Shiva also is a technical editor and contributor to multiple technical standards organizations and has defined and delivered compliance and interoperability methodologies. As a successful entrepreneur he founded the technology company Roseport Technologies, LLC and is currently launching and guiding other start-ups. He holds a masters degree in Electrical Engineering from Andhra University, Waltair, India
Kennedy leads go-to-market strategy and execution. He has over 27 years of product management, market development and sales leadership roles in the computer industry working across many enterprise segments including Healthcare and Life Sciences. He spent 25 years at Intel Corporation leading their high-end Xeon server product line and directing Data Center and IoT Solutions go-to-market in its two largest sales regions, the Americas and Europe, Middle East and Africa. He was responsible for driving >$5B in revenues for compute infrastructure solutions in AI, Analytics, Cloud and IoT. Recently, Kennedy was President of an AI solutions startup company called nlite.ai, and also consulted for startups and Fortune 100 companies on business development strategies. Kennedy holds a BS in Industrial & Systems Engineering from San Jose State University, and an MS in Industrial & Management Systems Engineering from Arizona State University.
Gershon Wolfe, PhD
Director of Research
Justin Kollman, PhD
Chair, Science & Technology Advisory Board
Joe Gray, PhD
Craig Yoshiaka, PhD
Dr. Wolfe leads development of machine learning techniques for image processing in drug discovery. He has a deep background in bioinformatics and algorithm development. As Vice President of Bioinformatics at Large Scale Biology (publicly traded: LSBC), he developed algorithms for full length gene discovery and annotation. Also, during his time at LSBC he developed a novel algorithmic discovery platform for mapping genes to metabolic pathways, this included assigning protein families using hidden Markov modeling and coupled this to a LIMS-RDBMS and GUI. This project turned into a suite of software that was eventually licensed to Dow Chemical and Dow AgroScience. As Vice President at Predictive Diagnostics, Gershon developed a machine learning technique that used blood plasma mass spectroscopy to detect the early onset of ovarian, lung, and prostate cancer, resulting in several publications and collaborations with NIH and PerkinElmer. At Advanced Ideas in Medicine (AIM), Gershon was a co-founder of a start-up company that used machine learning to detect cancer and perform a clinical trial for early detection of prostate cancer. At AIM, he was successful at securing angel-funding. Dr. Wolfe holds a B.S. in chemistry from UCLA and a Ph.D in chemical physics from the University of Washington. Gershon’s Ph.D. research was supported by winning a Royal Dutch Shell fellowship and a National Institute of Health molecular biophysics fellowship. After his Ph.D., Gershon was awarded a postdoctoral fellowship from UCSF.
Dr. Kollman is Chair of HTI's Science & Technology Advisory Board. Dr. Kollman is currently Associate Professor, Department of Biochemistry at the University of Washington. Justin holds a PhD in Biology from the University of California San Diego and completed a Postdoc in Biochemistry and Biophysics at the University of California San Francisco. He is currently a Director at the Arnold and Mabel Beckman Cryo-EM center at the University of Washington where his lab focuses on the structural biology of complex self-assembling protein structures, including metabolic enzyme polymers and force-generating bacterial nanomachines. Dr. Kollman has made numerous contributions to the field of X-Ray Crystallography and Cryo-EM and has held many positions on national committees such as the Advisory Board of the Centre for Cellular Evolution at McGill University, User Review committee at the Pacific Northwest Center for Cryo-EM, User Review Committee at the National Center for CryoEM Access and Training, and Instructor of CryoEM at Cold Spring Harbor Laboratories.
Dr. Kollman's publications can be found at
As a physicist and engineer by training, Dr. Gray is currently a faculty leader at Oregon Health & Science University as the Gordon Moore Endowed Chair of the Department of Biomedical Engineering, Director of OHSU Center for Spatial Systems Biomedicine (OCSSB), and Associate Director for Biophysical Oncology at the OHSU Knight Cancer Institute. He is also Emeritus Professor, University of California San Francisco; and Senior Scientist, Lawrence Berkeley National Laboratory, where he was previously Professor of Laboratory Medicine. For nearly 20 years, Joe was a Staff Scientist in the Biomedical Sciences Division of the Lawrence Livermore National Laboratory. He is the principal investigator of the National Cancer Institute/Integrative Cancer Biology Program Center for Cancer Systems Biology aimed at understanding and modeling of RTK signaling. The Gray Laboratory at OHSU explores mechanisms by which genomic, transcriptional and proteomic abnormalities occur in selected cancers, elucidates how these abnormalities contribute to cancer pathophysiologies and assesses the ways in which these abnormalities influence responses to gene targeted therapies. His work is described in more than 400 publications and in 73 US patents. Joe received his undergraduate degree in physics from the Colorado School of Mines and doctorate degree in physics from Kansas State University.
Dr. Yoshiaka is co-director of the National Cryo-EM Center at Oregon Health & Science University. Previously, Craig spent time at Nano-Imaging Services Inc. (a TEM service company) leading all of the company’s computing infrastructure, and was also awarded SBIR grants for prototyping further improvements to TEM tools. At OHSU, he works closely with the university’s high-performance computing group troubleshooting and planning infrastructure, and frequently assists on project collaborations between OHSU and industry partners focused on creating more efficient software and hardware for TEM data processing. Dr. Yoshioka has substantial experience maintaining installations of TEM software packages, and his published work implementing TEM processing tools has been cited over 150 times. Dr. Yoshioka’s cryo-EM experience includes significant work helping understand the molecular and mechanical basis behind the function of several crucial biological systems. Dr. Yoshioka’s accomplishments in these fields include: automating a single-particle data collection modality called RCT, improving the accuracy and speed of determining and correcting for a TEM imaging artifact called CTF, creating a very efficient and unbiased process for selecting single particles in micrographs, and creating a novel tool for interactive classification of heterogeneous datasets. Dr. Yoshioka holds a BS in Biochemistry from the University of Florida and a Ph.D. in Biophysics from The Scripps Research Institute.